Interference with protein-mediated intra- and intercellular pathways has become a major goal of preclinical and clinical research. A, rapidly increasing numBer of peptides are known to be responsible for endo-, para-and autocrine sig- nal transduction. These peptides and their receptors have been studied with regard to their cell growth stimulatory ac- tion and their impact on differentiation. In parallel, peptide antagonists are being investigated in terms of their potential role in preclinical and clinical application. ...
Read More
Interference with protein-mediated intra- and intercellular pathways has become a major goal of preclinical and clinical research. A, rapidly increasing numBer of peptides are known to be responsible for endo-, para-and autocrine sig- nal transduction. These peptides and their receptors have been studied with regard to their cell growth stimulatory ac- tion and their impact on differentiation. In parallel, peptide antagonists are being investigated in terms of their potential role in preclinical and clinical application. Thus, biotherapy might improve the clinical outcome of patients with tumors that respond to the respective hormonal manipulation. Among the numerous peptides of interest somatostatin (somatotropin release inhibitory factor) and the luteinizing hormone releasing hormone (LH-RH) have been the topic of intensive research during recent years. In this third vol- ume of peptides in oncology, experts in the field exten- sively review and update the mechanisms of action of so- matostatin and LH -RH -analogues in oncology. Somatostatin and its various short-and long-acting ana- logues have the unique feature of suppressing and inhibit- ing a wide range of cellular processes including cell prolif- eration. Receptors for these peptides which belong to the family of neuropeptides or neurotransmitters, are widely distributed, a feature which is not in keeping with the gen- eral view of a growth hormone regulatory system. LH -RH analogues play an established role in curative (adjuvant) and palliative treatment of hormone sensitive tumors.
Read Less
Add this copy of Peptides in Oncology III: Somatostatin and Lh-Rh to cart. $16.00, good condition, Sold by Tiber Books rated 4.0 out of 5 stars, ships from Cockeysville, MD, UNITED STATES, published 2000 by Springer, Berlin / New York.
Add this copy of Peptides in Oncology III: Somatostatin and Lh-Rh to cart. $18.00, very good condition, Sold by Bookmonger.Ltd rated 4.0 out of 5 stars, ships from Hillside, NJ, UNITED STATES, published 2000 by Springer.
Add this copy of Peptides in Oncology III to cart. $44.62, new condition, Sold by Media Smart rated 4.0 out of 5 stars, ships from Hawthorne, CA, UNITED STATES, published 1999 by Springer.
Add this copy of Peptides in Oncology III: Somatostatin and Lh-Rh to cart. $50.54, good condition, Sold by Bonita rated 4.0 out of 5 stars, ships from Newport Coast, CA, UNITED STATES, published 2000 by Springer.
Add this copy of Peptides in Oncology III: Somatostatin and Lh-Rh to cart. $103.32, new condition, Sold by Ingram Customer Returns Center rated 5.0 out of 5 stars, ships from NV, USA, published 2011 by Springer.
Add this copy of Peptides in Oncology III: Somatostatin and Lh-Rh to cart. $115.52, like new condition, Sold by GreatBookPrices rated 4.0 out of 5 stars, ships from Columbia, MD, UNITED STATES, published 2011 by Springer.
Choose your shipping method in Checkout. Costs may vary based on destination.
Seller's Description:
Fine. Trade paperback (US). Glued binding. 98 p. Contains: Tables, black & white. Recent Results in Cancer Research, 153. In Stock. 100% Money Back Guarantee. Brand New, Perfect Condition, allow 4-14 business days for standard shipping. To Alaska, Hawaii, U.S. protectorate, P.O. box, and APO/FPO addresses allow 4-28 business days for Standard shipping. No expedited shipping. All orders placed with expedited shipping will be cancelled. Over 3, 000, 000 happy customers.
Add this copy of Peptides in Oncology III: Somatostatin and Lh-Rh to cart. $115.77, new condition, Sold by GreatBookPrices rated 4.0 out of 5 stars, ships from Columbia, MD, UNITED STATES, published 2011 by Springer.
Choose your shipping method in Checkout. Costs may vary based on destination.
Seller's Description:
New. Trade paperback (US). Glued binding. 98 p. Contains: Tables, black & white. Recent Results in Cancer Research, 153. In Stock. 100% Money Back Guarantee. Brand New, Perfect Condition, allow 4-14 business days for standard shipping. To Alaska, Hawaii, U.S. protectorate, P.O. box, and APO/FPO addresses allow 4-28 business days for Standard shipping. No expedited shipping. All orders placed with expedited shipping will be cancelled. Over 3, 000, 000 happy customers.
![Peptides in Oncology III: Somatostatin and Lh-Rh Analogues [Recent Results in Cancer Research, Volume 153]](https://www0.alibris-static.com/isbn/9783642640384_t.gif)
